8-KShareholder MattersCorporate ChangesOther Events+1

BeOne Medicines Ltd. 8-K Report, Rights Modification (Dec 17, 2021)

Filed December 17, 2021For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on December 17, 2021, to report significant amendments to its Memorandum and Articles of Association. These changes are primarily driven by the company's successful initial public offering (IPO) on the Shanghai Stock Exchange's Science and Technology Innovation Board (STAR Market). The amendments aim to align the company's governance with Chinese securities regulations and enhance operational flexibility for its dual-listed shares. Key updates include modifications to share transfer procedures to accommodate electronic transfers recognized by the STAR Market, and new provisions for holding general meetings, allowing for physical, hybrid, or electronic formats to better facilitate shareholder participation, especially for those holding Renminbi (RMB) shares. Notably, the company has also established the U.S. federal district courts as the exclusive forum for resolving disputes related to the U.S. Securities Act of 1933, a common practice for companies with significant U.S. investor bases.

Key Highlights

  • 1BeiGene, Ltd. (ONC) amended its Memorandum and Articles of Association, effective December 15, 2021.
  • 2These amendments were necessary to comply with regulations related to its IPO on the Shanghai Stock Exchange's STAR Market.
  • 3Share transfer requirements have been updated to recognize electronic transfers as valid, facilitating trading on the STAR Market.
  • 4The company can now hold general meetings in physical, hybrid, or electronic formats.
  • 5Shareholders of RMB Shares will have facilitated access to attend general meetings via an online voting platform, considered presence in person.
  • 6U.S. federal district courts are designated as the exclusive forum for resolving claims under the U.S. Securities Act of 1933, unless the company consents otherwise.
  • 7The filing also confirms the closing of BeiGene's RMB 22.2 billion (US$3.5 billion) IPO on the STAR Market.

Frequently Asked Questions

The primary reason for the amendments is to comply with the Rules Governing the Listing of Securities on the STAR Market and other applicable securities regulations in China, following the company's initial public offering on the Shanghai Stock Exchange.

The amendments update the articles to recognize electronic transfers of shares as valid, satisfying the requirement for a formal instrument of transfer, which is essential for trading on the STAR Market.

The company can now hold general meetings as physical, hybrid, or electronic meetings. This provides greater flexibility in engaging with shareholders, especially for those holding Renminbi (RMB) shares who will be facilitated through an online voting platform.

This clause designates U.S. federal district courts as the exclusive venue for resolving lawsuits related to the U.S. Securities Act of 1933. This provision aims to consolidate litigation and provide a predictable legal environment for disputes involving the company's securities in the U.S.